US 12173314
Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
granted A61KA61K48/0058A61K48/0075
Quick answer
US patent 12173314 (Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes) held by United States Government as represented by the Department of Veterans Affairs expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- United States Government as represented by the Department of Veterans Affairs
- Grant date
- Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K48/0058, A61K48/0075, A61K48/0091, A61P